Shedding Light on PARP Inhibitor Response through Functional Imaging.

Authors :: Liu YL
Zamarin D
Source :: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2023 Apr 14; Vol. 29 (8), pp. 1384-1386.
Publication Year :: 2023
Abstract: Functional PET imaging using a PARP inhibitor (PARPi) analog may serve as an early, dynamic biomarker of response to PARPi therapy in high-grade serous ovarian cancer. Clinically, this could help to rapidly identify PARPi nonresponders, thereby maximizing efficacy and avoiding toxicities of futile treatments. See related article by Pantel et al., p. 1515.<br /> (©2023 American Association for Cancer Research.)

Subjects :: Female
Humans
Poly(ADP-ribose) Polymerase Inhibitors pharmacology
Poly(ADP-ribose) Polymerase Inhibitors therapeutic use
Pilot Projects
Biomarkers
Ovarian Neoplasms diagnostic imaging
Ovarian Neoplasms drug therapy
Antineoplastic Agents therapeutic use

Language :: English
ISSN :: 1557-3265
Volume :: 29
Issue :: 8
Database :: MEDLINE
Journal :: Clinical cancer research : an official journal of the American Association for Cancer Research
Publication Type :: Report
Accession number :: 36700799
Full Text :: https://doi.org/10.1158/1078-0432.CCR-22-3711